Početna › Multipli mijelom › Illinois
Kliničke studije za Multipli mijelom u državi Illinois
31 studija za Multipli mijelom traži sudionike na lokacijama u državi Illinois.
Gradovi u državi Illinois
- Chicago22 studija
- Cicero6 studija
- Waukegan4 studija
- Evanston4 studija
- Springfield4 studija
- Peoria3 studija
- Bloomington3 studija
- Decatur3 studija
- Aurora3 studija
- Galesburg3 studija
- North Peoria3 studija
Službeni tekst studije (engleski)
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- i još 13
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT06948084A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- University of Chicago Medical Center /ID# 278863, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chicago
- Research Site, Park Ridge
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Rush University System for Health, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Chicago, Zion
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University Of Illinois Medical Center, Chicago
- Loyola University Medical Center, Maywood
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Northwestern University, Chicago
- University of Chicago, Chicago
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05201781Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT05789303TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Chicago, Chicago
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06297226Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- University of Illinois at Chicago, Chicago
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT05344833MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Endeavor Health - Swedish Hospital, Chicago
- Endeavor Health - Evanston Hospital, Evanston
- Endeavor Health - Glenbrook Hospital Ambulatory Care Center, Glenview
- i još 6
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- i još 40
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Chicago
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Loyola University Medical Center, Maywood
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT07280013Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 3. kol 2026. · NCT06960993Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
- Loyola University Chicago, Maywood
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 22. srp 2026. · NCT07236502A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Hope And Healing Cancer Services /ID# 268536, Hinsdale
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT05650632Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Personalized Autologous Transplant for Multiple Myeloma
- University Illinois Chicago, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 15. lip 2026. · NCT04483206Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Anthony's Health, Alton
- Rush - Copley Medical Center, Aurora
- Saint Joseph Medical Center, Bloomington
- i još 41
U tijeku regrutacijaFaza 3
Sve dobne skupine · Oba spola · Ažurirano 10. lip 2026. · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT05243797Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
U tijeku regrutacijaFaza 1
Od 13 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT04771572Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- University of Chicago Medical Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. tra 2026. · NCT05862012Hypofractionation (Radiation) Trial for Multiple Myeloma
- The University of Chicago Comprehensive Cancer Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ožu 2026. · NCT06270888A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 24. ožu 2026. · NCT04988555Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 23. velj 2026. · NCT05974150A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- City of Hope at Chicago, Zion
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 20. velj 2026. · NCT07225738Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
- University of Illinois Cancer Center, Chicago
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 18. pro 2025. · NCT05192122Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.